Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Prostate cancer often earns the label “silent killer” because it can develop and progress for years without producing noticeable symptoms. Understanding this timeline becomes crucial for men seeking ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Prostate cancer is one of the most common cancers among men in the U.S. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, according to the American Cancer Society. But experts ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

When it comes to detecting cancer, you want the fastest detection possible in order to treat it accurately and in a timely ...

Prostate cancer is the second leading cause of cancer-related death in men, behind heart disease. According to the American Cancer Society, about one in eight men will be diagnosed with prostate ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

For asymptomatic people without known risks, the downsides and uncertainties of multi-cancer early detection testing could ...